Importer of Controlled Substances; Notice of Application, 45779-45780 [E8-17976]
Download as PDF
<![CDATA[
45779
Federal Register / Vol. 73, No. 152 / Wednesday, August 6, 2008 / Notices
Justice will receive comments relating to
the Consent Decree. Comments should
be addressed to the Assistant Attorney
General, Environment and Natural
Resources Division, and either e-mailed
to pubcomment-ees.enrd@usdoj.gov or
mailed to P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611. In either case, the
comments should refer to United States
v. Morrison Enterprises, LLC, and
Cooperative Producers, Inc., Civil
Action No. 8:08–00332–JFB–TDT, D.J.
Ref. No. 90–11–3–431/2.
The decree may be examined at the
Office of the United States Attorney,
District of Nebraska, 1620 Dodge Street,
Suite 1400, Omaha, Nebraska, 68102.
During the comment period, the
Consent Decree may be examined on the
following Department of Justice website:
https://www.usdoj.gov/enrd/
Consent_Decrees.html . A copy of the
Consent Decree may also be obtained by
mail from the Consent Decree Library,
P.O. Box 7611, U.S. Department of
Justice, Washington, DC 20044–7611, or
by faxing or e-mailing a request to Tonia
Fleetwood (tonia.fleetwood@usdoj.gov),
fax no. (202) 514–0097, phone
confirmation number (202) 514–1547. In
requesting a copy from the Consent
Decree Library, please enclose a check
in the amount of $38.00 (25 cents per
page reproduction cost) payable to the
United States Treasury or, if by e-mail
or fax, forward a check in that amount
to the Consent Decree Library at the
stated address.
Robert E. Maher, Jr.,
Assistant Section Chief Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. E8–18044 Filed 8–5–08; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on PROD1PC66 with NOTICES
Importer of Controlled Substances;
Notice of Application
Pursuant to Title 21 Code of Federal
Regulations 1301.34(a), this is notice
that on May 27, 2008, Chattem
Chemicals, Inc., 3801 St. Elmo Avenue,
Building 18, Chattanooga, Tennessee
37409, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as an importer of
the basic classes of controlled
substances listed in schedule II:
Drug
Schedule
Methamphetamine (1105) .............
Phenylacetone (8501) ...................
VerDate Aug<31>2005
16:46 Aug 05, 2008
Drug
Schedule
Raw Opium (9600) .......................
Concentrate of Poppy Straw
(9670).
The company plans to import the
listed controlled substances to
manufacture bulk controlled substances
for sale to its customers.
No comments, objections, or requests
for any hearings will be accepted on any
application for registration or reregistration to import crude opium,
poppy straw, concentrate of poppy
straw, and coca leaves. As explained in
the Correction to Notice of Application
pertaining to Rhodes Technologies, 72
FR 3417 (January 25, 2007), comments
and requests for hearing on applications
to import narcotic raw material are not
appropriate.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than September 5, 2008.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substance listed in
schedule I or II are, and will continue
to be, required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
II
II
Jkt 214001
II
II
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
Dated: July 29, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–17975 Filed 8–5–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on June
11, 2008, Almac Clinical Services Inc.
(ACSI), 2661 Audubon Road, Audubon,
Pennsylvania 19403, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in schedule
II:
Drug
Oxycodone (9143) ........................
Fentanyl (9801) .............................
Schedule
II
II
The company plans to import small
quantities of the listed controlled
substances in dosage form to conduct
clinical trials.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be
filed no later than September 5, 2008.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
E:\FR\FM\06AUN1.SGM
06AUN1
45780
Federal Register / Vol. 73, No. 152 / Wednesday, August 6, 2008 / Notices
in a previous notice published in the
Federal Register on September 23, 1975
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: July 29, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–17976 Filed 8–4–08; 8:45 am]
BILLING CODE 4410–09–P
Dated: July 29, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–17977 Filed 8–4–08; 8:45 am]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on PROD1PC66 with NOTICES
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on June 2,
2008, Wildlife Laboratories, 1401 Duff
Drive, Suite 400, Fort Collins, Colorado
80524, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
Etorphine Hydrochloride (9059), a basic
class of controlled substance listed in
schedule II.
The company plans to import the
listed controlled substance for sale to its
customers.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
VerDate Aug<31>2005
16:46 Aug 05, 2008
Jkt 214001
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than September 5, 2008.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substance listed in
schedule I or II are, and will continue
to be, required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on March
26, 2008, BA Research International
LLC, 10550 Rockley Road, Suite 150,
Houston, Texas 77099–0000, made
application to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Schedule
4-Methylaminorex (cis isomer)
(1590).
Gamma
Hydroxybutyric
Acid
(2010).
Methaqualone (2565) ....................
Ibogaine (7260) .............................
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
I
I
I
I
Drug
Lysergic acid diethylamide (7315)
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) ......
Cannabidiol (7372) .......................
Mescaline (7381) ..........................
4-Methyl-2,5-dimethoxyamphetamine (7395).
3,4-Methylenedioxyamphetamine
(7400).
3,4-Methylenedioxymethamphetamine (7405).
Peyote (7415) ...............................
Bufotenine (7433) .........................
Diethyltryptamine (7434) ...............
Dimethyltryptamine (7435) ............
Psilocybin (7437) ..........................
Etorphine (except HCL) (9056) ....
Heroin (9200) ................................
Normorphine (9313) ......................
Alphacetylmethadol except levoalphacetylmethadol (9603).
Amphetamine (1100) ....................
Methamphetamine (1105) .............
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Diprenorphine (9058) ....................
Etorphine HCL (9059) ...................
Oxycodone (9143) ........................
Hydromorphone (9150) .................
Diphenoxylate (9170) ....................
Ethylmorphine (9190) ...................
Levorphanol (9220) .......................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Thebaine (9333) ...........................
Opium, raw (9600) ........................
Opium, powdered (9639) ..............
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ....................
Fentanyl (9801) .............................
Hydrocodone (9193) .....................
Meperidine (9230) .........................
Methadone (9250) ........................
Morphine (9300) ...........................
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import
analytical reference standards for
analytical testing of blood samples from
clinical trials.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
E:\FR\FM\06AUN1.SGM
06AUN1
]]>Agencies
[Federal Register Volume 73, Number 152 (Wednesday, August 6, 2008)]
[Notices]
[Pages 45779-45780]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-17976]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on June 11, 2008, Almac Clinical Services Inc. (ACSI), 2661
Audubon Road, Audubon, Pennsylvania 19403, made application by renewal
to the Drug Enforcement Administration (DEA) to be registered as an
importer of the basic classes of controlled substances listed in
schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Oxycodone (9143)............................ II
Fentanyl (9801)............................. II
------------------------------------------------------------------------
The company plans to import small quantities of the listed
controlled substances in dosage form to conduct clinical trials.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43 and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, VA 22152; and must be filed no later
than September 5, 2008.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted
[[Page 45780]]
in a previous notice published in the Federal Register on September 23,
1975 (40 FR 43745), all applicants for registration to import a basic
class of any controlled substance in schedule I or II are, and will
continue to be, required to demonstrate to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, that the requirements for such registration pursuant to
21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d),
(e), and (f) are satisfied.
Dated: July 29, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-17976 Filed 8-4-08; 8:45 am]
BILLING CODE 4410-09-P
